Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew W Michell

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
BMC Medical Research Methodology|May 29, 2009
Visualising disease progression on multiple variables with vector plots and path plotsStanley E Lazic, Sarah L Mason, Andrew W Michell, et al.
Journal of Neuroimmunology|April 8, 2014
Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitisJ William L Brown, Peter J Martin, John W Thorpe, et al.
Annals of Clinical and Translational Neurology|May 19, 2022
Remyelination in humans due to a retinoid-X receptor agonist is age-dependentChristopher E McMurran, Trisha Mukherjee, J William L Brown, et al.
Neurophotonics|July 23, 2016
Hemodynamic response to burst-suppressed and discontinuous electroencephalography activity in infants with hypoxic ischemic encephalopathyMaria Chalia, Chuen Wai Lee, Laura A Dempsey, et al.
Neurophotonics|February 18, 2020
Errata: Hemodynamic response to burst-suppressed and discontinuous electroencephalography activity in infants with hypoxic ischemic encephalopathyMaria Chalia, Chuen Wai Lee, Laura A Dempsey, et al.
Brain : a Journal of Neurology|February 9, 2006
Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profilesBenjamin R Underwood, David Broadhurst, Warwick B Dunn, et al.
The Lancet. Neurology|January 13, 2012
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept studyPeter Connick, Madhan Kolappan, Charles Crawley, et al.
Annals of Neurology|March 19, 2011
Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitisSarosh R Irani, Andrew W Michell, Bethan Lang, et al.
Trials|March 4, 2011
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsPeter Connick, Madhan Kolappan, Rickie Patani, et al.
The Lancet. Neurology|August 21, 2021
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a studyJ William L Brown, Nick G Cunniffe, Ferran Prados, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
BMC Medical Research Methodology|May 29, 2009
Visualising disease progression on multiple variables with vector plots and path plotsStanley E Lazic, Sarah L Mason, Andrew W Michell, et al.
Journal of Neuroimmunology|April 8, 2014
Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitisJ William L Brown, Peter J Martin, John W Thorpe, et al.
Annals of Clinical and Translational Neurology|May 19, 2022
Remyelination in humans due to a retinoid-X receptor agonist is age-dependentChristopher E McMurran, Trisha Mukherjee, J William L Brown, et al.
Neurophotonics|July 23, 2016
Hemodynamic response to burst-suppressed and discontinuous electroencephalography activity in infants with hypoxic ischemic encephalopathyMaria Chalia, Chuen Wai Lee, Laura A Dempsey, et al.
Neurophotonics|February 18, 2020
Errata: Hemodynamic response to burst-suppressed and discontinuous electroencephalography activity in infants with hypoxic ischemic encephalopathyMaria Chalia, Chuen Wai Lee, Laura A Dempsey, et al.
Brain : a Journal of Neurology|February 9, 2006
Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profilesBenjamin R Underwood, David Broadhurst, Warwick B Dunn, et al.
The Lancet. Neurology|January 13, 2012
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept studyPeter Connick, Madhan Kolappan, Charles Crawley, et al.
Annals of Neurology|March 19, 2011
Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitisSarosh R Irani, Andrew W Michell, Bethan Lang, et al.
Trials|March 4, 2011
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsPeter Connick, Madhan Kolappan, Rickie Patani, et al.
The Lancet. Neurology|August 21, 2021
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a studyJ William L Brown, Nick G Cunniffe, Ferran Prados, et al.
Pageof 2